Last Updated: November 8, 2026

Glenmark Pharms Company Profile

What is the competitive landscape for GLENMARK PHARMS

GLENMARK PHARMS has one hundred and seventy-two approved drugs.

There are seven tentative approvals on GLENMARK PHARMS drugs.

Summary for Glenmark Pharms

US Patents:	0
Tradenames:	138
Ingredients:	130
NDAs:	172

Drugs and US Patents for Glenmark Pharms

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Pharms Ltd	SODIUM PHENYLBUTYRATE	sodium phenylbutyrate	TABLET;ORAL	216462-001	Nov 1, 2022	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Glenmark Pharms Ltd	TOPIRAMATE	topiramate	CAPSULE, EXTENDED RELEASE;ORAL	210278-003	Feb 1, 2021	AB2	RX	No	No		⤷ Start Trial				⤷ Start Trial
Glenmark Pharms Ltd	RALOXIFENE HYDROCHLORIDE	raloxifene hydrochloride	TABLET;ORAL	204491-001	Mar 22, 2016	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Paragraph IV (Patent) Challenges for GLENMARK PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.